-
Meta Analysis
Prognosis and clinicopathological characteristics of metaplastic breast cancer: A meta-analysis.
- Xiaolu Yang, Tiantian Tang, and Tao Zhou.
- Department of Breast Cancer Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
- Medicine (Baltimore). 2022 Dec 9; 101 (49): e32226e32226.
BackgroundTo compare the clinicopathological characteristics and prognosis of metaplastic breast cancer (MBC) and triple-negative breast cancer (TNBC).MethodsA meta-analysis was performed on relevant cohort or case-control studies retrieved by a literature search of the PubMed, EMBASE, Ovid, and Web of Science databases. Hazard ratio (HR) was used to evaluate disease-free survival (DFS) and overall survival (OS), and the odds ratio (OR) and corresponding 95% confidence interval (CI) was used to evaluate clinicopathological characteristics, including age, tumor diameter, lymph node metastasis status, distant metastasis status, TNM staging, and histological grade.ResultsNine studies were included in the meta-analysis. Compared with TNBC patients, the HRs for 5-year DFS and 5-year OS of those with MBC were 1.64 (95% confidence interval [CI] 1.36 - 1.98; P < .001) and 1.52 (95% CI 1.27 - 1.81; P < .001), respectively. The OR for age ≥ 50 years, tumor diameter ≤ 5 cm, lymph node-negative, distant metastasis, TNM stage III and IV, and histological grade 3 was 1.63 (95% CI 1.45-1.84), 0.29 (95% CI 0.14-0.58), 1.46 (95% CI 1.13-1.88), 1.59 (95% CI 0.89-2.81), 1.49 (95% CI 0.80-2.77), and 2.25 (95% CI 0.85-5.97), respectively.ConclusionPatients with MBC had worse prognosis than those with TNBC. Furthermore, regarding clinicopathological characteristics, patients with MBC mostly presented at ≥ 50 years of age, with tumor diameter > 5 cm, and negative lymph nodes at first diagnosis. Moreover, there were no statistically significant differences in the occurrence of distant metastasis, TNM stages III and IV, or histological grade 3. MBC treatment was not assessed in this study. Data from randomized controlled trials are needed to guide the treatment of patients with MBC.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*
,_underline_
or**bold**
. - Superscript can be denoted by
<sup>text</sup>
and subscript<sub>text</sub>
. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3.
, hyphens-
or asterisks*
. - Links can be included with:
[my link to pubmed](http://pubmed.com)
- Images can be included with:
![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
- For footnotes use
[^1](This is a footnote.)
inline. - Or use an inline reference
[^1]
to refer to a longer footnote elseweher in the document[^1]: This is a long footnote.
.